These findings suggest that pioglitazone-pretreated MSCs could be an effective candidate for MSC-based therapeutics for patients with CKD, and that understanding of the regulation of NF-κB–PINK-1 may provide important insights regarding mitochondrial potential. This evidence concerns the gene PINK1 and chronic kidney disease.